Loading company…
Japanese biotech founded in 2017 that develops nucleic acid drugs and oligonucleotide therapeutics with pharmaceutical partners.
Founded in 2017 and based in Japan, Luxna Biotech Co., Ltd. works in nucleic acid editing and drug creation, including oligonucleotide therapeutics and cancer research. It develops nucleic acid drugs using artificial nucleic acids in collaboration with pharmaceutical and chemical companies. In August 2025 the company raised JPY 150 million in Series C funding from new investors Mitsubishi UFJ Capital, Kobe University Capital and Resona Capital, to support business development, drug discovery partnerships and out-licensing.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in